169 related articles for article (PubMed ID: 35104500)
1. Atractylon, a novel dopamine 2 receptor agonist, ameliorates Parkinsonian like motor dysfunctions in MPTP-induced mice.
Li H; Wang F; Zhou Z; Jiang X; Li F; Feng Y; Liu C; Zhang Y; Fan S; Wu X; Huang C
Neurotoxicology; 2022 Mar; 89():121-126. PubMed ID: 35104500
[TBL] [Abstract][Full Text] [Related]
2. Pepper component 7-ethoxy-4-methylcoumarin, a novel dopamine D2 receptor agonist, ameliorates experimental Parkinson's disease in mice and Caenorhabditis elegans.
Li H; Feng Y; Chen Z; Jiang X; Zhou Z; Yuan J; Li F; Zhang Y; Huang X; Fan S; Wu X; Huang C
Pharmacol Res; 2021 Jan; 163():105220. PubMed ID: 33007422
[TBL] [Abstract][Full Text] [Related]
3. Gait Deficits and Loss of Striatal Tyrosine Hydroxlase/Trk-B are Restored Following 7,8-Dihydroxyflavone Treatment in a Progressive MPTP Mouse Model of Parkinson's Disease.
Massaquoi MS; Liguore WA; Churchill MJ; Moore C; Melrose HL; Meshul CK
Neuroscience; 2020 May; 433():53-71. PubMed ID: 32142862
[TBL] [Abstract][Full Text] [Related]
4. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
[TBL] [Abstract][Full Text] [Related]
5. The Neuroprotective Effects of GPR4 Inhibition through the Attenuation of Caspase Mediated Apoptotic Cell Death in an MPTP Induced Mouse Model of Parkinson's Disease.
Haque ME; Azam S; Akther M; Cho DY; Kim IS; Choi DK
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925146
[TBL] [Abstract][Full Text] [Related]
6. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective Effects of the DPP4 Inhibitor Vildagliptin in In Vivo and In Vitro Models of Parkinson's Disease.
Pariyar R; Bastola T; Lee DH; Seo J
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216503
[TBL] [Abstract][Full Text] [Related]
8. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
L'Episcopo F; Tirolo C; Caniglia S; Testa N; Serra PA; Impagnatiello F; Morale MC; Marchetti B
J Neuroinflammation; 2010 Nov; 7():83. PubMed ID: 21092260
[TBL] [Abstract][Full Text] [Related]
9. Quantitative assessment of gait and neurochemical correlation in a classical murine model of Parkinson's disease.
Wang XH; Lu G; Hu X; Tsang KS; Kwong WH; Wu FX; Meng HW; Jiang S; Liu SW; Ng HK; Poon WS
BMC Neurosci; 2012 Nov; 13():142. PubMed ID: 23151254
[TBL] [Abstract][Full Text] [Related]
10. Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease.
Sconce MD; Churchill MJ; Greene RE; Meshul CK
Neuroscience; 2015 Jul; 299():156-74. PubMed ID: 25943481
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of ATP production ameliorates motor and cognitive impairments in a mouse model of MPTP-induced Parkinson's disease.
Haga H; Matsuo K; Yabuki Y; Zhang C; Han F; Fukunaga K
Neurochem Int; 2019 Oct; 129():104492. PubMed ID: 31229554
[TBL] [Abstract][Full Text] [Related]
12. Ursolic acid attenuates oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in MPTP-induced Parkinsonian mouse model.
Rai SN; Yadav SK; Singh D; Singh SP
J Chem Neuroanat; 2016 Jan; 71():41-9. PubMed ID: 26686287
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease.
Liu LX; Chen WF; Xie JX; Wong MS
Neurosci Res; 2008 Feb; 60(2):156-61. PubMed ID: 18054104
[TBL] [Abstract][Full Text] [Related]
14. Single low doses of MPTP decrease tyrosine hydroxylase expression in the absence of overt neuron loss.
Alam G; Edler M; Burchfield S; Richardson JR
Neurotoxicology; 2017 May; 60():99-106. PubMed ID: 28377118
[TBL] [Abstract][Full Text] [Related]
15. Nobiletin treatment improves motor and cognitive deficits seen in MPTP-induced Parkinson model mice.
Yabuki Y; Ohizumi Y; Yokosuka A; Mimaki Y; Fukunaga K
Neuroscience; 2014 Feb; 259():126-41. PubMed ID: 24316474
[TBL] [Abstract][Full Text] [Related]
16. Exercise in an animal model of Parkinson's disease: Motor recovery but not restoration of the nigrostriatal pathway.
Churchill MJ; Pflibsen L; Sconce MD; Moore C; Kim K; Meshul CK
Neuroscience; 2017 Sep; 359():224-247. PubMed ID: 28754312
[TBL] [Abstract][Full Text] [Related]
17. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.
Breidert T; Callebert J; Heneka MT; Landreth G; Launay JM; Hirsch EC
J Neurochem; 2002 Aug; 82(3):615-24. PubMed ID: 12153485
[TBL] [Abstract][Full Text] [Related]
18. Effect of inhibition of fatty acid amide hydrolase on MPTP-induced dopaminergic neuronal damage.
Viveros-Paredes JM; Gonzalez-Castañeda RE; Escalante-Castañeda A; Tejeda-Martínez AR; Castañeda-Achutiguí F; Flores-Soto ME
Neurologia (Engl Ed); 2019 Apr; 34(3):143-152. PubMed ID: 28104279
[TBL] [Abstract][Full Text] [Related]
19. Novel FABP3 ligand, HY-11-9, ameliorates neuropathological deficits in MPTP-induced Parkinsonism in mice.
Wang H; Fukunaga K; Cheng A; Wang Y; Arimura N; Yoshino H; Sasaki T; Kawahata I
J Pharmacol Sci; 2023 May; 152(1):30-38. PubMed ID: 37059489
[TBL] [Abstract][Full Text] [Related]
20. Expression of peroxisome proliferator-activated receptor-gamma in the substantia nigra of hemiparkinsonian nonhuman primates.
Swanson C; Emborg M
Neurol Res; 2014 Jul; 36(7):634-46. PubMed ID: 24620964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]